



PharmAust launches international CEO search

13 April 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, advises that as the Company moves to more advanced trial milestones, the Board of Directors has commenced a search for a new Australian-based Chief Executive Officer.

The Board is seeking a CEO with strong knowledge in FDA certification and global licensing agreements as PAA advances medium-term milestones:

- Preparation for Phase 3 trial for Canine B-Cell Lymphoma
- Further commercialisation strategies for Canine B Cell Lymphoma
- Mid-Phase 1 readout of Motor Neuron Disease (MND) interim analysis
- Preparation for Phase 2 MND trial
- Determine the optimal human cancer and Principal Investigator for a Phase 2 human cancer trial

The chosen individual will display proven abilities in regular contact and communication with the investment community.

Dr Roger Aston will remain as Chairman of the Board but will transition into a non-executive role assisting with his 40 years' experience in the pharmaceutical and healthcare industry.

The Board will continue to ensure that PharmAust has the necessary expertise, industry experience and diversity to expedite drug development and commercialisation for treatments of cancers and viral and neurological diseases.

The Board has authorised this announcement.

Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (PAA) and the Frankfurt Stock Exchange (ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL showed objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treating human and veterinary cancers and neurodegenerative diseases as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com